Introduction
Iridoviruses are large, icosahedral, double-stranded DNA viruses. They exist in two forms: non-enveloped particles 120-180 nm in diameter and enveloped particles that result from budding from the plasma membrane. In addition to the external envelope, some iridoviruses contain a fringe of fine fibers (fibrils) that extend outward from the capsid subunits (Chinchar et al. 2011) . Non-enveloped particles are composed of three distinct layers: an outer capsid composed of multiple copies of an ~50 kDa major capsid protein (MCP), an internal lipid membrane possibly derived from the endoplasmic reticulum (ER) or other cellular membranes, and an inner core containing the viral genome and associated viral-encoded proteins. Although both forms are infectious, enveloped virions were shown to have higher specific infectivities (Braunwald et al. 1985; Chinchar et al. 2011; Yan et al. 2000) .
ranavirus (King et al. 2012) . SGIV enters grouper cells via the clathrin-mediated endocytic pathway and macropinocytosis in a pH-dependent manner, and it is transported along both microtubules and actin filaments (Wang et al. 2014 ).
Replication involves the nuclear and cytoplasmic compartments and utilizes host and viral enzymes. SGIV induces non-apoptotic cell death in spleen cells in vitro, and causes enlargement of the spleen with hemorrhaging in vivo (Huang et al. 2011) .
SGIV infection has a greater than 90% mortality rate in grouper and sea bass (Qin et al. 2003) . However, despite the high mortality rate, no effective treatment for SVIG infection is available.
To prevent serious iridovirus infections, studies have been conducted that used polyclonal or monoclonal antibodies to discover antigenic structures in iridoviruses (Wan et al. 2010) . Viral surface antigens are localized mainly to the outer envelope or capsid surface of virions (Cheng et al. 2006; Monini and Ruggeri 2002) . Proteomics and bioinformatics are believed to be efficient approaches in the field of functional genomics, and they have been widely used to analyze viral structural proteins.
Currently, the genome sequence, viral transcription program, and global landscape of structural proteins of SGIV have been investigated (Song et al. 2004 (Song et al. , 2006 Teng et al. 2008) . SGIV VP39 was revealed to be a conserved iridovirus core gene, and it was predicted to be a serine/threonine protein kinase (Eaton et al. 2007 ) that was able to phosphorylate recombinant SGIV ORF075R (Wang et al.2008) . In this study, VP39
was identified and shown to be a viral envelope protein, and its localization was determined. Recombinant VP39 (rVP39) was expressed in Escherichia coli. An D r a f t 5 antibody against rVP39 was developed, and its ability to inhibit SGIV infection was investigated. All these data will provide new insights into our understanding of the structural protein composition of SGIV.
Materials and methods

Virus and cell cultures
SGIV (strain A3/12/98 PPD) was propagated on grouper spleen (GS) cell monolayers as previously described (Qin et al. 2001) . SGIV was stored at −80°C until use. GS cells were derived from the orange-spotted grouper, Epinephelus coioides (Qin et al. 2006) and were cultured at 25°C in Leibovitz's L-15 medium containing 10% fetal bovine serum (Gibco-BRL, Grand Island, NY, USA) and subcultured at a ratio of 1:3 every four days.
Sequence analysis
The sequence of the SGIV VP39 gene was analyzed against the National Center GeneDoc software. The phylogenetic tree was established using MEGA 5.1 software, with the neighbor-joining (NJ) method and bootstrapping (1000 replicates). The
GenBank accession numbers of VP39 homologs from different iridoviruses used in the phylogenetic analysis are listed in Table 1 .
Prokaryotic expression, protein purification, and antibody preparation
The recombinant plasmid pET-rVP39 was transformed into E. coli BL21 cells, and His-tag fusion protein expression was induced with 0.7 mM isopropyl β-D-1-thiogalactopyranoside(IPTG) at 37°C for 4 h. The fusion protein was purified from inclusion bodies under denaturing conditions using the His-Bind Purification kit (Novagen, Merck KGaA, Darmstadt, Germany) Reverse transcription-polymerase chain reaction (RT-PCR) and western blot analyses GS cells were infected with SGIV at a multiplicity of infection (MOI) of approximately 1. Total RNA was isolated from mock and virus-infected cells at 4, 6, 8, 12, 16, 20, 24, 36 , and 48 h post-infection (p.i.) using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After the RNA was digested with RNase-free DNase, 1 µg of RNA from each time point was transcribed using Moloney murine leukemia virus reverse transcriptase (M-MLV RT) and random primers to synthesize the first-strand cDNA. Polymerase Chain Reaction (PCR) was then performed using the primers pair P1/P2 (5′-TGTACCGCTTACTAAATGCC-3′
and 5′-GAGTTCCTCCGCTGATGTTA-3′, respectively). Detection of β-actin mRNA using the primer pair P3/P4 (5′-CACTGTGCCCATCTACGAG-3′ and 5′-CCATCTCCTGCTCGAAGTC-3′, respectively, GenBank: GU145294.1) was used as an internal control. In addition, cycloheximide (CHX) and cytosine β-D-arabinofuranoside (AraC) were used to classify the temporal expression of SGIV VP39 during infection. Briefly, GS monolayers were pretreated with 50 µg/ml CHX or 100 µg/ml AraC for 1 h before and throughout the SGIV infection. CHX-or
AraC-pretreated cells were mock-infected or infected with SGIV at an MOI of approximately 1, and then harvested at 6 and 48 h p.i., respectively. Total RNA was isolated, and VP39 transcription was analyzed by RT-PCR. The β-actin gene was used as a control.
To examine the protein expression pattern, western blotting was performed on protein extracts from samples collected at the same time points as described above.
Equivalent amounts of cell extracts were electrophoresed on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA, USA). Mouse anti-VP39 serum was used as the primary antibody at a dilution of 1:3,000, and the secondary antibody was horseradish peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich) at a dilution of 1:3,000. Simultaneous internal controls were performed by detecting the β-actin protein with an anti-β-actin antibody (Boster Biologics, Pleasanton, CA, USA; 1:3,000).
Indirect immunofluorescence assay
The subcellular localization of SGIV VP39 was determined by immunofluorescence microscopy. GS cells, grown on cover slips in six-well plates, were infected with SGIV at an MOI of approximately 2. Mock-infected cells were used as a control. At 24 h p.i., the cells were fixed with 4% formaldehyde at 4°C for 1 h and permeabilized with 0.2% Triton X-100 in phosphate-buffered saline (PBS).
After blocking with 2% bovine serum albumen (BSA), the cover slips were incubated at a dilution of 1:75 for 2 h at room temperature, and then stained with 1 µg/ml 4',6'-diamidino-2'-phenylindole (DAPI, Sigma-Aldrich) for 10 min at room temperature. It was necessary to wash the cover slips three times with PBS between each step. Simultaneous controls were performed by detecting SGIV VP72 (the MCP) with mouse anti-VP72 serum. The samples were examined by fluorescence microscopy (Leica, Wetzlar, Germany).
Virus purification and envelope extraction
SGIV purification was performed as described previously by Qin et al. (2001 Qin et al. ( , 2003 , with modifications. Briefly, virus was inoculated onto confluent monolayers of GS cells at an MOI of 1. When an advanced cytopathic effect (CPE) was observed, the cell cultures, including medium containing SGIV, were harvested and subjected to three cycles of rapid freezing/thawing and ultrasonication. The suspension containing the lysate, virus, and cellular debris was then centrifuged at 12,000 × g for 30 min at 4°C. The supernatant was centrifuged at 210,000 × g for 2 h at 4°C. The pellet was resuspended in PBS, and overlaid onto 20-60% (w/v) sucrose gradients and centrifuged at 210,000 × g for 1 h at 4°C. The virus band was collected and diluted with PBS. The virion pellets were finally collected after 1 h of centrifugation at 100,000 × g at 4°C and suspended in PBS, and then stored at −80°C until used.
D r a f t
Envelope proteins were extracted according to the methods of Zhao et al. (2008) .
Briefly, purified SGIV particles were treated with an equal volume of 1% Triton X-100 (150 mM NaCl, 50 mM Tris, pH 7.5) for 30 min at room temperature, and centrifuged at 20,000 × g for 30 min at 4°C. The supernatant was collected as the envelope fraction, and the pellet was treated with 1% Triton X-100 for 30 min and centrifuged again to further remove the viral envelope proteins, and then the resulting pellet was collected as the non-envelope fraction.
Analysis of VP39 by matrix-assisted laser desorption/ionization-time of flight tandem mass spectrometry
The extracted envelope proteins of SGIV were separated by SDS-PAGE and 
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Immunogold electron microscopy
Purified SGIV virus particles were adsorbed onto Formvar-coated, carbonstabilized 200-mesh nickel grids (Ted Pella, Inc, CA, USA) for 1 h at room temperature. After washing with PBS, the grids were blocked with 3% BSA for 1 h and then rinsed with PBS, followed by incubation with mouse anti-VP39 serum as the primary antibody (1:100, diluted in 3% BSA) for 2 h at 37°C. After washing five times with PBS, 10 nm gold-labeled anti-mouse goat IgG (Sigma-Aldrich) was added to the grids as the secondary antibody and incubated for 1 h at 25°C. Grids were washed three more times with PBS and stained with 2% phosphotungstic acid (pH 7.0) for 1 min. Specimens were examined under a transmission electron microscope (JEM-100CX II, JEOL, Tokyo, Japan). As a control experiment, pre-immune serum and mouse anti-SGIV VP72 serum were used in the same way.
Antibody neutralization assay
The neutralization titer of the mouse anti-VP39 polyclonal antibody was evaluated by a micro neutralization test as described by Zhang et al. (2010) . GS cells were cultured in a 96-well cell culture plate. Inactivated mouse anti-rVP39 serum was serially diluted from 1:1 to 1:128. Each virus dilution was repeated four times. A TCID 50 of 0.1 should not cause the CPE, while a TCID 50 of 100 must cause the CPE, otherwise, the test cannot be established. The 50% serum neutralized dose was calculated by the Reed-Muench method (Reed and Muench 1938) .
Results
Sequence analysis of SGIV VP39
The To better understand the evolutionary history of SGIV VP39, its deduced amino acid sequence was compared to those of grouper iridovirus (GIV), tiger frog virus identities among members of the iridoviruses differed greatly, and SGIV was most closely related to GIV, as they are likely isolates of the same viral species.
Transcriptional analysis of SGIV VP39 in SGIV-infected GS cells
The temporal expression pattern of SGIV VP39 in GS cells during viral infection was characterized at both the RNA and protein levels by RT-PCR and western blot analyses, respectively. SGIV VP39 transcription was first detected at 8 h p.i. (Fig. 2A) , and translation was first detected at 12 h p.i. (Fig. 2B ). Both the transcription and translation signal intensities increased during the viral infection.
To examine the temporal expression of SGIV VP39 during infection, total RNA was extracted from protein synthesis inhibitor (CHX)-and DNA synthesis inhibitor (AraC)-treated GS cells after SGIV infection. As shown by RT-PCR (Fig. 2C ), VP39 expression was inhibited in the presence of CHX or AraC, but it was expressed in the sample infected with SGIV at 48 h p.i., thus indicating that the SGIV-VP39 RNA might be a late viral transcript.
Indirect immunofluorescence assay
An indirect immunofluorescence assay was performed to identify the expression patterns and subcellular location of the SGIV VP39. The nucleic acids of GS cells and viruses within assembly sites were stained blue with DAPI, while the viral protein VP39 was indicated by green fluorescence. As shown in Fig. 3 , at 12 h p.i., the green fluorescence signal was distributed in both the cytoplasm and the nucleus of 
Identification of VP39 as an envelope protein by Western blot and MS analyses
Proteins of the SGIV-infected cells, including virions, nucleocapsids, and the envelope fractions, were separated by 12% SDS-PAGE. Western blot results showed that the polyclonal mouse anti-rVP39 antiserum reacted strongly with an approximately 120 kDa SGIV envelope protein (Fig. 4A) , thereby confirming that VP39 is a viral envelope protein.
The results of the western blot analysis showed that VP39 was associated with a single distinct protein band from the viral envelope. The band corresponding to the approximately 120 kDa protein was excised from the gel and subjected to MALDI TOF/TOF MS/MS analyses. Fourteen peptide masses were found to match the predicted peptide masses of VP39 within 100 mg/l, covering 15% of its amino acid sequence (Fig. 4B) . The measured and calculated masses of the tryptic peptides of the MS/MS spectra are shown in Fig. 4C .
Searching the SGIV open reading frame (ORF) database with the tryptic peptide masses showed that one of the proteins was encoded by ORF039L. This means that the resulting amino acid sequences matched that of VP39.
D r a f t
Immunogold electron microscopy
The location of the viral protein VP39 on SGIV virions was determined using immunogold electron microscopy. Purified virions showed a well-defined hexagonal outline (Fig. 5A) . No gold particles were found on the envelopes of virions when using pre-immune serum as the primary antibody (Fig. 5B) . A high density of gold particles was observed on the envelope of the virions when using mouse anti-SGIV VP39 serum as the primary antibody (Fig. 5C ), but very few gold particles were bound to the envelope of the virions when using mouse anti-SGIV MCP serum as the primary antibody (Fig. 5D ). After treatment with Triton X-100 (1%) for 30 min, the viral envelope was almost completely removed, and the viral capsid appeared as a bright ring around the electron-dense core ( Fig. 5E ) (indicated by arrows). The envelope of the virions was degraded, and very few gold particles were found on the viral capsid when using the pre-immune serum (Fig. 5F ) or mouse anti-SGIV VP39 serum as the primary antibody (Fig. 5G ). After treatment with 1% Triton X-100 for 30 min, the viral capsid was visible, and the capsid was labeled with a high density of gold particles when using mouse anti-SGIV MCP serum as the primary antibody (Fig.   5H ).
Antibody neutralization assay
To investigate whether SGIV VP39 is involved in virus infection, neutralization assays using antibodies against the VP39 protein were performed on SGIV-infected GS cells. Neutralization was calculated by determining the infectivity of SGIV.
D r a f t
Infectivity was calculated as the ratio of plaque-forming units (PFUs) for each virus preparation that was incubated with the corresponding dilution of antibody relative to the number of PFUs obtained by incubating with media alone. From this, the 50% serum neutralized titer was calculated. As shown in Fig. 6 , the neutralization titer of the mouse anti-SGIV VP39 polyclonal antibody was 1:16.
Antisera raised against individual viral envelope proteins have been used successfully in neutralization assays to identify envelope proteins involved in viral infections (Schofield et al. 2000; Wu et al. 2005) . In this study, the antibody neutralization assays indicated that the mouse anti-VP39 serum neutralizes SGIV.
Therefore, SGIV VP39 is likely to be involved in systemic SGIV infections.
Discussion
SGIV ORF39L had been predicted to encode a viral structural protein (Song et al. 2004 ). ORF39L was identified as a core gene of the family Iridoviridae, and it was predicted to be a serine/threonine protein kinase (Eaton et al. 2007) . expression of viral late genes and virion assembly (Wang et al. 2008 ). In addition, bioinformatics analysis also indicated that VP39 has two cysteine-rich adaptor domains, which were also found in vaccinia virus membrane protein A16.
Cysteine-rich motifs in viral membrane proteins were confirmed to be required for Iridovirus genes are expressed in three main temporal kinetic expression classes:
IE, early (E), and late (L) (Williams et al. 2007 ). IE, E, and L genes can be defined experimentally using the protein synthesis inhibitor CHX and the DNA replication inhibitor AraC (Nalcacioglu et al. 2003 (Nalcacioglu et al. , 2007 
